title: The effects of montelukast on eosinophilic gastroenteritis in a mouse model.
abstract: Gastrointestinal eosinophilic (EG) is a rare and heterogeneous condition characterized by patchy or diffuse eosinophilic infiltration of gastrointestinal tissue. Pharmacological study so far has demonstrated that montelukast, an oral leukotriene receptor antagonist, might be considered in patients with this disease. The aim of this study was to evaluate the effect of montelukast on oral ovalbumin (OVA) allergen induced EG inflammation in mice and to suggest some mechanisms underlying this effect. Twenty-four mice were divided into three experimental groups: PBS control, OVA group, and montelukast treated group. The mice were sensitized intraperitoneally and challenged intragastrically with OVA, and were treated with montelukast. Gastrointestinal symptoms were observed after challenged intragastrically with OVA. Eosinophils count in blood, serum OVA specific IgE and gastrointestinal histology were evaluated. Montelukast could significantly reduce the severity of oral allergen-induced eosinophilic inflammation, villous atrophy, and associated symptoms of weight loss associated with diarrhea. Montelukast also could ameliorate OVA-induced gastrointestinal pathological lesions, which was associated with the decrease of IgE and LTD4 levels, and this might be one of the important mechanisms of montelukast that protected gastrointestinal injury from EG. These findings indicated that montelukast therapy may be a novel therapeutic approach for EG and other eosinophil-mediated diseases.
authors.affiliation: Provincial Hospital Affiliated to Shandong University, Jinan, 250014, PR China.
authors.forename: Daihong
authors.initials: D
authors.lastname: Wan
authors.forename: Xuemei
authors.initials: X
authors.lastname: Liu
authors.forename: Guimei
authors.initials: G
authors.lastname: Li
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003521:Cyclopropanes; D004751:Enteritis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004802:Eosinophilia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D005756:Gastritis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005759:Gastroenteritis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D007073:Immunoglobulin E / Q000378:metabolism; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D007583:Jejunum / Q000187:drug effects / Q000378:metabolism; D017998:Leukotriene D4 / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin; D011804:Quinolines / Q000494:pharmacology*; D013270:Stomach / Q000187:drug effects; D013440:Sulfides
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D007073:Immunoglobulin E; D017998:Leukotriene D4; D010047:Ovalbumin; C093875:montelukast